Hybrid Insulin Peptides in Type 1 Diabetes: How They Form and Why They Matter
Immunological Reviews · 2026
DOI: 10.1111/imr.70185 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2026. Verfasst von Kelly Douglas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora,…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Autoantigens, CD4-Positive T-Lymphocytes. Die Arbeit nennt 74 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes is a T cell‐mediated autoimmune disease that leads to the destruction of the insulin‐producing beta cells of the pancreas, yet the antigens that drive this response have been difficult to define. This review traces the identification of hybrid insulin peptides (HIPs), posttranslationally modified autoantigens formed when a fragment of insulin is joined through a peptide bond to a fragment of a second beta cell granule protein, creating a sequence not encoded by any single gene. Beginning with the search for the antigen of the diabetogenic BDC‐2.5 clone in the nonobese diabetic (NOD) mouse, we show that its natural ligand is a hybrid of an insulin C‐peptide fragment and a peptide derived from chromogranin A, and that subsequent mass spectrometry analyses defined a set of disease‐relevant HIPs supported by both T cell reactivity and detection of the endogenous peptide. We summarize the recognition of HIPs by CD4 T cells across several HLA class II alleles in human disease, the enzymatic and nonenzymatic routes of HIP formation within acidic secretory and crinophagic compartments, and genetic evidence that reducing HIP formation delays diabetes. Finally, we propose a multi‐trigger model linking a species difference in HIP formation to the focal, episodic islet pathology of human type 1 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
ORCID-Profile: Thomas Delong
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Douglas, K., & Delong, T. (2026). Hybrid Insulin Peptides in Type 1 Diabetes: How They Form and Why They Matter. Immunological Reviews. https://doi.org/10.1111/imr.70185
Vancouver
Douglas K, Delong T. Hybrid Insulin Peptides in Type 1 Diabetes: How They Form and Why They Matter. Immunological Reviews. 2026. doi:10.1111/imr.70185
BibTeX
@article{Douglas2026,
author = {Douglas, Kelly and Delong, Thomas},
title = {Hybrid Insulin Peptides in Type 1 Diabetes: How They Form and Why They Matter},
journal = {Immunological Reviews},
year = {2026},
doi = {10.1111/imr.70185}
}
EUVIMED